Hørsholm, Denmark – April 23, 2025
Lunatus and AFYX Therapeutics A/S are pleased to announce a new distribution and sales collaboration for AFYX’s induction of labor product, Gefena (Misoprostol 25μg tablet). Under this agreement, Lunatus will distribute, commercialize and supply Gefena in the following countries: United Arab Emirates, Qatar, Kuwait, Oman, Kingdom of Saudi Arabia, Bahrain, Iraq, and Jordan. Gefena is expected to receive EU regulatory approval in Q4 2025. Gefena is designed to induce labor in pregnant women who have surpassed their scheduled delivery date.
Claus Møller-San Pedro
CEO & Founder
About Lunatus and AFYX Therapeutics A/S
Lunatus is dedicated to partnering with leading biopharmaceutical companies, broadening, and accelerating global patient access to innovative treatments utilizing its unique core competencies and know-how to effectively introduce cutting edge therapies and pharmaceuticals.
Visti: https://lunatus.com/
At AFYX, Reversed Innovation is our core value. As a leader in the biopharmaceutical industry, we focus on repurposing existing products or technologies to address new or previously overlooked medical conditions.
Visti: https://afyxtx.com
For more information, please contact:
Lunatus:
Mina Ashraf – Mina.ashraf@lunatus.com
Maricel Magtibay – Maricel@lunatus.com
+971 4 399 4755 / +971 4 208 9333
AFYX Therapeutics A/S
Pia Laursen – pcl@afyxtx.com
+45 2320 1914